Gout drug shows promise for diabetic kidney protection in small trial
NCT ID NCT07177898
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This completed study tested whether adding allopurinol (a gout medication) to standard lisinopril treatment could better protect kidneys in people with type 2 diabetes. 80 patients with normal uric acid levels were split into two groups: one received both drugs, the other lisinopril alone. Researchers tracked kidney function over a year to see if urine albumin levels rose, a sign of kidney damage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
allopurinol and lisinopril
What this could lead to
If adding allopurinol works, it could offer a simple, low-cost way to help protect kidneys in people with type 2 diabetes.
What could go wrong
This is a small, single-center study with only 80 participants. Results may not apply to everyone, and the benefit might be small or not confirmed in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
King Edward Medical University
Lahore, Punjab Province, 54000, Pakistan